Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05228470 · FLOW

Participant flow

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · Source last updated 2026-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received subcutaneous (SC) elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 (C1D1) and 32 mg on Cycle 1 Day 4 (C1D4) followed by 76 mg weekly (QW) thereafter starting from Cycle 1 Day 8. Each cycle was 28 days. If a participant had received QW dosing for at least 6 cycles and had achieved a partial response (PR) or better persisting for at least 2 months, the dose interval was changed to once every 2 weeks (Q2W).
    id
    FG000
    title
    Phase 1b
  2. description
    Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8. Each cycle was 28 days. If a participant had received QW dosing for at least 6 cycles and had achieved a PR or better persisting for at least 2 months, the dose interval was changed to Q2W.
    id
    FG001
    title
    Phase 2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        11
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        8
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        11
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        30
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        30
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 38 participants were enrolled and assigned to study treatment. Data for only those primary and secondary outcome measures whose analysis is complete and final have been reported. Data for remaining secondary outcome measures will be posted upon completion of analysis at study completion date.
recruitment Details
Chinese participants with relapsed/refractory multiple myeloma (RRMM), who were refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-cluster of differentiation38 monoclonal antibody (anti-CD38 mAB) were included.
Complete source fields
groups
  1. description
    Participants received subcutaneous (SC) elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 (C1D1) and 32 mg on Cycle 1 Day 4 (C1D4) followed by 76 mg weekly (QW) thereafter starting from Cycle 1 Day 8. Each cycle was 28 days. If a participant had received QW dosing for at least 6 cycles and had achieved a partial response (PR) or better persisting for at least 2 months, the dose interval was changed to once every 2 weeks (Q2W).
    id
    FG000
    title
    Phase 1b
  2. description
    Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8. Each cycle was 28 days. If a participant had received QW dosing for at least 6 cycles and had achieved a PR or better persisting for at least 2 months, the dose interval was changed to Q2W.
    id
    FG001
    title
    Phase 2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        11
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        8
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        11
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        30
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        30
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 38 participants were enrolled and assigned to study treatment. Data for only those primary and secondary outcome measures whose analysis is complete and final have been reported. Data for remaining secondary outcome measures will be posted upon completion of analysis at study completion date.
recruitment Details
Chinese participants with relapsed/refractory multiple myeloma (RRMM), who were refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-cluster of differentiation38 monoclonal antibody (anti-CD38 mAB) were included.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice